If all groups were not included in the baseline template, some might not be considered by the big pharmaceutical companies, intent on making commercial drugs linked to specific genotypes. Dr. Jackson pointed out that minorities can not assume inclusiveness at any stage of the HGP and that the pattern of sampling often reflects power relationships. On the second morning, Dr. Daniel Drell of the DOE Human Genome Program presented a review of the HGP and a recap of the first day s proceedings. A panel on Ethical, Legal, and Social Implications of the HGP for Minorities included Phyllis Epps, Esq. These profiles are compared to those collected in other cases waiting to be solved.
All states have legislation allowing the collection of DNA samples from convicted offenders.
As a result, drug manufacturers, researchers, and physicians will have legitimate reasons to consider race in judging the effectiveness of medicines. Given past history, patients will regard race-based treatment with suspicion, and the medical community will find it a great challenge to balance the benefits of different treatments against the risks inherent in classifying persons by race for whatever reason. Create more training opportunities for veteran teachers in such scientific developments as genetics. Create settings that will develop good scientific mentoring situations for minority students. Increase minority student awareness of the large number and types of jobs and careers needed in the genomic, biomedical, and biotechnology industries.